Literature DB >> 16010522

Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

J J Meier1, B Gallwitz, M Askenas, K Vollmer, C F Deacon, J J Holst, W E Schmidt, M A Nauck.   

Abstract

AIMS/HYPOTHESIS: The insulinotropic effect of gastric inhibitory polypeptide (GIP) is reduced in patients with type 2 diabetes and around 50% of their first-degree relatives under hyperglycaemic conditions. It is unknown whether this is a result of a specific defect in GIP action or of a general reduction in beta cell function. Moreover, impaired secretion of glucagon-like peptide 1 (GLP-1) has been described in patients with type 2 diabetes. Therefore, we studied the insulinotropic effect of GIP in women with previous gestational diabetes (pGDM) under euglycaemic fasting conditions and during a hyperglycaemic clamp experiment. The secretion of GIP and GLP-1 was assessed following oral glucose ingestion.
MATERIALS AND METHODS: On separate occasions we performed an OGTT and administered an i.v. bolus of 20 pmol GIP/kg body weight in 20 women with pGDM and 20 control women. An additional hyperglycaemic clamp experiment (140 mg/dl [7.8 mmol/l] over 120 min) with i.v. infusion of GIP (2 pmol kg(-1) min(-1); 30-90 min) was performed in 14 women in each group. Capillary and venous blood samples were drawn for the measurement of glucose (glucose oxidase), insulin, C-peptide, GIP and GLP-1 (specific immunoassays). Indices of insulin sensitivity and beta cell function were calculated. Statistical analyses were carried out using repeated measures ANOVA.
RESULTS: Following oral glucose ingestion, plasma glucose, insulin and C-peptide concentrations increased to higher levels in the women with pGDM than in the control women (p<0.05). The women with pGDM were characterised by a higher degree of insulin resistance than the control women (p=0.007 for the Matsuda index), but showed no overt defects in glucose-stimulated insulin secretion (p=0.40 for the insulinogenic index following i.v. glucose). The secretion of GLP-1 and GIP was not different between the groups (p=0.87 and p=0.57, respectively). The insulin secretory response to GIP administration was similar in the two groups both after GIP bolus administration and during the hyperglycaemic clamp experiment (p=0.99 and p=0.88, respectively). A hyperbola-like relationship was found between the degree of insulin sensitivity (Matsuda index) and the insulin secretory response to GIP and i.v. glucose administration. CONCLUSIONS/
INTERPRETATION: These results do not support the hypothesis of an early defect in GIP action as a risk factor for subsequent development of diabetes in women with previous gestational diabetes. The inverse relationship between insulin resistance and the insulin secretory response to glucose or GIP suggests that beta cell secretory function in response to different stimuli increases adaptively when insulin sensitivity is diminished.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16010522     DOI: 10.1007/s00125-005-1863-7

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  43 in total

1.  The pathogenesis of NIDDM involves a defective expression of the GIP receptor.

Authors:  J J Holst; J Gromada; M A Nauck
Journal:  Diabetologia       Date:  1997-08       Impact factor: 10.122

Review 2.  The incretin concept today.

Authors:  W Creutzfeldt
Journal:  Diabetologia       Date:  1979-02       Impact factor: 10.122

3.  The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion.

Authors:  I R Jones; D R Owens; A J Moody; S D Luzio; T Morris; T M Hayes
Journal:  Diabetologia       Date:  1987-09       Impact factor: 10.122

4.  Multiple metabolic defects during late pregnancy in women at high risk for type 2 diabetes.

Authors:  A H Xiang; R K Peters; E Trigo; S L Kjos; W P Lee; T A Buchanan
Journal:  Diabetes       Date:  1999-04       Impact factor: 9.461

5.  Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.

Authors:  Juris J Meier; Baptist Gallwitz; Bartholomaeus Kask; Carolyn F Deacon; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Journal:  Diabetes       Date:  2004-12       Impact factor: 9.461

6.  Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.

Authors:  Michael A Nauck; Andrea El-Ouaghlidi; Bartholomäus Gabrys; Katrin Hücking; Jens J Holst; Carolyn F Deacon; Baptist Gallwitz; Wolfgang E Schmidt; Juris J Meier
Journal:  Regul Pept       Date:  2004-11-15

Review 7.  The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

Authors:  J E Gerich
Journal:  Endocr Rev       Date:  1998-08       Impact factor: 19.871

8.  Glucose tolerance, insulin release, and insulin sensitivity in normal-weight women with previous gestational diabetes mellitus.

Authors:  S Efendić; U Hanson; B Persson; A Wajngot; R Luft
Journal:  Diabetes       Date:  1987-04       Impact factor: 9.461

9.  Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.

Authors:  T Krarup; N Saurbrey; A J Moody; C Kühl; S Madsbad
Journal:  Metabolism       Date:  1987-07       Impact factor: 8.694

Review 10.  Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.

Authors:  R N Bergman
Journal:  Diabetes       Date:  1989-12       Impact factor: 9.461

View more
  23 in total

Review 1.  Impact of postprandial glycaemia on health and prevention of disease.

Authors:  E E Blaak; J-M Antoine; D Benton; I Björck; L Bozzetto; F Brouns; M Diamant; L Dye; T Hulshof; J J Holst; D J Lamport; M Laville; C L Lawton; A Meheust; A Nilson; S Normand; A A Rivellese; S Theis; S S Torekov; S Vinoy
Journal:  Obes Rev       Date:  2012-07-11       Impact factor: 9.213

Review 2.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

3.  Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice.

Authors:  N Irwin; P L McClean; F P M O'Harte; V A Gault; P Harriott; P R Flatt
Journal:  Diabetologia       Date:  2007-05-08       Impact factor: 10.122

4.  Thioamide Substitution Selectively Modulates Proteolysis and Receptor Activity of Therapeutic Peptide Hormones.

Authors:  Xing Chen; Elizabeth G Mietlicki-Baase; Taylor M Barrett; Lauren E McGrath; Kieran Koch-Laskowski; John J Ferrie; Matthew R Hayes; E James Petersson
Journal:  J Am Chem Soc       Date:  2017-11-13       Impact factor: 15.419

Review 5.  Physiology of incretins in health and disease.

Authors:  Carolyn F Deacon; Bo Ahrén
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 6.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

7.  Reduction of insulinotropic properties of GLP-1 and GIP after glucocorticoid-induced insulin resistance.

Authors:  Marie Eriksen; David H Jensen; Siri Tribler; Jens J Holst; Sten Madsbad; Thure Krarup
Journal:  Diabetologia       Date:  2015-03-09       Impact factor: 10.122

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

Review 9.  Maternal metabolism and obesity: modifiable determinants of pregnancy outcome.

Authors:  Scott M Nelson; Phillippa Matthews; Lucilla Poston
Journal:  Hum Reprod Update       Date:  2009-12-04       Impact factor: 15.610

Review 10.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.